* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on May 9 for
the period ending March 31 2024
* The South Jordan Utah-based company is expected to report
a
1.3% increase in revenue to $74.802 million from $73.87 million
a year ago, according to the mean estimate from 16 analysts,
based on LSEG data.The company's guidance on February 22 2024,
for the period ended March 31, was for revenue between $72.50
million and $76.50 million.
* LSEG's mean analyst estimate for Health Catalyst Inc is
for
earnings of 3 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $11.50, above its last closing price of $6.78.
The company's guidance on February 22 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD72.5 million and USD4 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.01 0.00 0.02 Beat 2,700
Sep. 30 2023 0.00 -0.02 0.03 Beat 275.6
Jun. 30 2023 -0.01 0.00 0.05 Beat 1,447.
7
Mar. 31 2023 -0.04 -0.04 0.05 Beat 222.9
Dec. -0.11 -0.11 -0.05 Beat 55.8
31 2022
Sep. 30 2022 -0.18 -0.19 -0.13 Beat 32.8
Jun. 30 2022 -0.09 -0.10 -0.03 Beat 70.2
Mar. 31 2022 -0.09 -0.11 -0.06 Beat 47.6
This summary was machine generated May 8 at 02:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)